A multi-centre, stratified, open, randomized, comparator-controlled, parallel-group phase III study comparing treatment with 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in patients with inoperable, progressive, somatostatin receptor positive, midgut carcinoid tumours

Trial Profile

A multi-centre, stratified, open, randomized, comparator-controlled, parallel-group phase III study comparing treatment with 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in patients with inoperable, progressive, somatostatin receptor positive, midgut carcinoid tumours

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 01 Feb 2018

At a glance

  • Drugs Lutetium-(177Lu)-oxodotreotide (Primary) ; Amino acids; Octreotide
  • Indications Carcinoid tumour; Neuroendocrine tumours
  • Focus Registrational; Therapeutic Use
  • Acronyms NETTER-1
  • Sponsors Advanced Accelerator Applications
  • Most Recent Events

    • 01 Feb 2018 According to an Advanced Accelerator Applications media release, Advanced Accelerator Applications is acquired by Novartis
    • 26 Jan 2018 Results presented in a Novartis Media Release.
    • 26 Jan 2018 According to a Food and drug administration media release, based on results from this and a phase I/II trial (please see CT profile 700269588) study the U.S. Food and Drug Administration today approved Lutathera (lutetium Lu 177 dotatate) for the treatment of a type of cancer that affects the pancreas or gastrointestinal tract called gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top